Trial Profile
A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects With Elevated Intraocular Pressure
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Latanoprost/netarsudil (Primary) ; Latanoprost; Netarsudil
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms Mercury 1
- Sponsors Aerie Pharmaceuticals
Most Recent Events
- 12 Mar 2020 Results (n=1468) for pooled analysis of the MERCURY-1 and -2 studies assessing efficacy analysis at 3 months, and a pooled safety analysis up to 12 months. published in the Advances in Therapy
- 12 Mar 2019 According to an Aerie Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.This approval is based on the data from MERCURY 1 and MERCURY 2 trials.
- 23 Jul 2018 According to an Aerie Pharmaceuticals media release, company received Early the Day 74 notification from the U.S. Food and Drug Administration (FDA) earlier than scheduled, the FDA has completed its initial 60-day review of the NDA (new drug application) for Roclatan with PDUFA Date Set for March 14, 2019.